The FDA has approved a pre-market approval (PMA) application from Intersect ENT for its Propel mometasone furoate drug delivery implant for the treatment of chronic sinusitis. The dissolvable device is inserted in the sinus cavity during surgery and maintains the opening of the ethnoid sinus while it delivers the corticosteroid to the sinus lining. David W. … [Read more...] about FDA approves mometasone nasal implant for chronic sinusitis
News
Aegis Therapeutics gets patent for GLP-1 peptide analog formulations for intranasal delivery
Aegis Therapeutics has received US Patent No. 7,998,927 for stabilized formulations of GLP-1 peptide analogs that can be delivered by a variety of different routes, including intranasal. All currently available GLP-1 formulations, which can control blood sugar and affect weight, such as Lilly-Amylin's Byetta and Novo Nordisk's Victoza require once- or twice-daily … [Read more...] about Aegis Therapeutics gets patent for GLP-1 peptide analog formulations for intranasal delivery
NexBio reports clinical trial results for inhaled antiviral
NexBio, which was recently raided by the US Federal Bureau of Investigation (FBI), has announced results from a Phase 2 clinical trial of its Fludase inhaled antiviral for the treatment of influenza. According to the company, the dry powder formulation, also known as DAS181, demonstrated a significant reduction of viral load in patients infected with influenza. The … [Read more...] about NexBio reports clinical trial results for inhaled antiviral
Pulmatrix gets $14 million for inhaled COPD and CF therapy development
Massacheusetts biotech company Pulmatrix has secured $14 million in additional funding from its existing investors, including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund, bringing its total to $60 million. Terry McGuire, General Partner of Polaris Venture Partners commented, “We believe that Pulmatrix’s iCALM products have … [Read more...] about Pulmatrix gets $14 million for inhaled COPD and CF therapy development
MAP Pharmaceuticals gets US patent for Levadex inhaled DHE
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile," to MAP Pharmaceuticals for its Levadex inhaled dihydroergotamine (DHE) technology. The patent will expire in 2028. "We have designed LEVADEX to … [Read more...] about MAP Pharmaceuticals gets US patent for Levadex inhaled DHE
MannKind and FDA agree on design of new inhaled insulin trials
After a meeting with the FDA, MannKind Corporation has announced that the company and the agency have confirmed protocols for new efficacy and safety studies of Afrezza inhaled insulin. The original studies of Afrezza were conducted with MedTone inhaler, and in May, the FDA asked MannKind to conduct new trials with the new Dreamboat inhaler in patients with type 1 … [Read more...] about MannKind and FDA agree on design of new inhaled insulin trials
Akela discontinues inhaled fentanyl development program
Akela Pharma is looking for a buyer for its Taifun fentanyl development program after Teikoku Seiyaku returned Japanese rights to the product. The dry powder inhaler (DPI) was being developed for the treatment of breakthrough pain in cancer patients. Akela is also in negotiations with another development partner, Janssen Pharmaceutica, for the return of the remaining … [Read more...] about Akela discontinues inhaled fentanyl development program
MAP hires Frederick Graff to lead launch of inhaled migraine drug
MAP Pharmaceuticals has hired Frederick H. Graff as VP, Commercial Operations, a position newly created in anticipation of a potential launch of the company's Levadex inhaled dihydroergotamine (DHE) for the treatment of migraine. Graff was previously Senior VP of Sales at Sepracor, where he led the launch of Xopenex levalbuterol inhalation solution. The announcement … [Read more...] about MAP hires Frederick Graff to lead launch of inhaled migraine drug
FDA accepts NDA for Teva HFA “dry” nasal spray
The US FDA has accepted the new drug application (NDA) filed by Teva on May 24, 2011 for its beclomethasone dipropionate (BDP) hydrofluoroalkane nasal spray for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). The BDP Nasal HFA spray uses the same formulation as Teva's Qvar inhalation aerosol, an inhaled corticosteroid (ICS) … [Read more...] about FDA accepts NDA for Teva HFA “dry” nasal spray
FBI raids developer of inhaled dry powder vaccine
According to news reports, the US Federal Bureau of Investigation (FBI) has raided the San Diego, California headquarters of vaccine developer NexBio and removed papers. FBI agent Darrell Foxworth is quoted as saying that the search warrant was in regard to " an ongoing investigation involving violations of criminal law." No arrests were reported. A local … [Read more...] about FBI raids developer of inhaled dry powder vaccine